Skip to contentT
TScan Therapeutics, Inc.
T
TCRXTScan Therapeutics, Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$2.57M$2.57Mderived+286.0% vs Q4 2024 Net Income-$22.98M-$22.98MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TScan Therapeutics, Inc. · CIK 1783328 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$23,858,000N/M Operating Cash Flowderived-$32,002,000N/M Free Cash Flowderived-$32,173,000N/M Margins · derivedOperating margin-929.4%+4591.2 pt vs Q4 2024
Net margin-895.1%+4489.7 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 4, 2026 · 63 d after period end